1. Home
  2. KODK vs ABUS Comparison

KODK vs ABUS Comparison

Compare KODK & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastman Kodak Company

KODK

Eastman Kodak Company

N/A

Current Price

$8.09

Market Cap

982.9M

ML Signal

N/A

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

N/A

Current Price

$4.08

Market Cap

836.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KODK
ABUS
Founded
1880
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
982.9M
836.0M
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
KODK
ABUS
Price
$8.09
$4.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
845.2K
★ 2.3M
Earning Date
11-03-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 55.26
EPS
0.11
★ 1.13
Revenue
★ $4,114,000,000.00
$14,083,000.00
Revenue This Year
$10.63
$1,208.75
Revenue Next Year
$6.60
N/A
P/E Ratio
$77.32
★ $3.59
Revenue Growth
N/A
★ 128.21
52 Week Low
$6.54
$3.50
52 Week High
$14.87
$5.45

Technical Indicators

Market Signals
Indicator
KODK
ABUS
Relative Strength Index (RSI) 39.83 47.64
Support Level $7.43 N/A
Resistance Level $10.11 $4.52
Average True Range (ATR) 0.41 0.21
MACD -0.02 0.02
Stochastic Oscillator 32.29 60.76

Price Performance

Historical Comparison
KODK
ABUS

About KODK Eastman Kodak Company

Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: